70 results
Page 2 of 4
424B5
0y2cnckkasjz56r
20 Jan 22
Prospectus supplement for primary offering
4:45pm
8-K
EX-1.1
8hrid92sjdyoefsp2
17 Nov 21
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9:04am
8-K
EX-99.1
9e5tmw6g1 ja
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
lhrj wwyvm9j
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
7c8e5q
6 Apr 20
Departure of Directors or Certain Officers
8:30am
424B5
mfcd9
9 Jan 20
Prospectus supplement for primary offering
5:25pm
8-K
EX-1.1
sh7x407snlfi44
9 Jan 20
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5:22pm